- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07789184
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
26. August 2026 aktualisiert von: Hua Huang, MD, PhD
A Prospective, Multicenter, Phase III Randomized Controlled Trial Evaluating the Impact of Radical Surgery Versus Non-Surgery on Prognosis and Quality of Life in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy (ALANO Study, CGCA2603 Study)
The goal of this clinical trial is to learn if radical surgery improves prognosis and quality of life compared with continued standard non-surgical treatment in gastric cancer patients with peritoneal metastasis who have achieved successful conversion therapy. The main questions it aims to answer are:
- Does radical surgery prolong overall survival in patients who achieve successful conversion therapy?
- Does radical surgery provide better or at least comparable quality of life and safety outcomes compared with continued standard treatment? Researchers will compare radical surgery versus continued standard systemic treatment to see whether radical surgery provides superior clinical benefit for patients after successful conversion therapy.
Participants will:
- Initial laparoscopic exploration confirms CY0P1 or CY1P1, absence of distant organ metastasis, a PCI ≤ 20, and presence or absence of ascites.
- Receive conversion therapy (chemotherapy, targeted/immunotherapy, intraperitoneal therapy, etc.) per standard guidelines, tailored to the patient's condition and molecular-pathological profile
- If clinical conversion is confirmed, undergo a second laparoscopic exploration to verify successful conversion
- If successful conversion is confirmed (peritoneal lesions cleared or markedly regressed with negative biopsy, no ascites or distant metastases, R0-resectable primary tumor, and improved patient condition), be randomized 1:1 to either the surgery group or the standard treatment group
- In the surgery group, undergo curative gastrectomy with D2 lymphadenectomy during the second laparoscopy, followed by adjuvant therapy and maintenance treatment
- In the standard treatment group, continue systemic therapy without surgery, with maintenance treatment and salvage surgery permitted if clinically indicated
- Complete quality of life questionnaires at predefined time points
- Be followed up for survival, disease progression, adverse events and medical resource use outcomes
Studienübersicht
Status
Noch keine Rekrutierung
Bedingungen
Studientyp
Interventionell
Einschreibung (Geschätzt)
170
Phase
- Phase 3
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Hua Huang
- Telefonnummer: +86-13816151816
- E-Mail: huahuang@fudan.edu.cn
Studienorte
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100853
- Chinese PLA General Hospital
-
Kontakt:
- xiaohui du
- Telefonnummer: +86 010-68182255
- E-Mail: duxiaohui301@sina.com
-
Beijing, Beijing Municipality, China, 102206
- Peking University International Hospital
-
Kontakt:
- ning ning
- Telefonnummer: +86 010-69006666
- E-Mail: ningning301@126.com
-
Beijing, Beijing Municipality, China, 100142
- Peking University Cancer Hospital
-
Kontakt:
- ziyu li
- Telefonnummer: +86 010-88121122
- E-Mail: ziyu_li@hsc.pku.edu.cn
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400038
- The First Affiliated Hospital of Army Medical University
-
Kontakt:
- yan shi
- Telefonnummer: +86 023-68765109
- E-Mail: shiyanpwk@tmmu.edu.cn
-
-
Fujian
-
Zhangzhou, Fujian, China, 363000
- Zhangzhou Affiliated hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
Kontakt:
- huiyan luo
- Telefonnummer: +86 020-87343571
- E-Mail: luohy@sysucc.org.cn
-
Guangzhou, Guangdong, China, 510515
- Nanfang Hospital, Southern Medical University
-
Kontakt:
- yanfeng hu
- Telefonnummer: +86 020-61641888
- E-Mail: banby@smu.edu.cn
-
Guangzhou, Guangdong, China, 510655
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Kontakt:
- shi chen
- Telefonnummer: +86 020-38254000
- E-Mail: chensh47@mail.sysu.edu.cn
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
-
Kontakt:
- guihua wang
- Telefonnummer: +86 027-83665555
- E-Mail: ghwang@tjh.tjmu.edu.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital
-
Kontakt:
- hao xu
- Telefonnummer: +86 025-83718836
- E-Mail: hxu@njmu.edu.cn
-
Nanjing, Jiangsu, China, 210009
- Jiangsu Cancer Hospital
-
Kontakt:
- chao yue
- Telefonnummer: +86 025-83283597
- E-Mail: yuechaomeng@126.com
-
Nanjing, Jiangsu, China, 210008
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School
-
Kontakt:
- jia wei
- Telefonnummer: +86 025-83106666
- E-Mail: jiawei99@nju.edu.cn
-
Nantong, Jiangsu, China, 226001
- Nantong First People's Hospital
-
Kontakt:
- shichun feng
- Telefonnummer: +86 0513-81111888
- E-Mail: fsc2200@126.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The First Affiliated Hospital of Nanchang University
-
Kontakt:
- zhengrong li
- Telefonnummer: +86 0791-88692748
- E-Mail: lzr13@foxmail.com
-
Nanchang, Jiangxi, China, 330006
- The Second Affiliated Hospital of Nanchang University
-
Kontakt:
- bin lai
- Telefonnummer: +86 0791-86120120
- E-Mail: Vincent83126@163.com
-
Shangrao, Jiangxi, China, 334000
- Shangrao People's Hospital
-
Kontakt:
- jinqiang chen
- Telefonnummer: +86 0793-8100469
- E-Mail: CJQ760624@126.com
-
-
Jilin
-
Changchun, Jilin, China, 130021
- The First Hospital of Jilin University
-
Kontakt:
- quan wang
- Telefonnummer: +86 0431-88782222
- E-Mail: wquan@jlu.edu.cn
-
-
Liaoning
-
Dalian, Liaoning, China, 116011
- The First Affiliated Hospital of Dalian Medical University
-
Kontakt:
- pin liang
- Telefonnummer: +86 0411-83635963
- E-Mail: sunnyliangpin@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Kontakt:
- peng xia
- Telefonnummer: +86 029-85323200
- E-Mail: peng_xia666@126.com
-
Xi'an, Shaanxi, China, 710038
- The Second Affiliated Hospital of Airforce Military Medical University
-
Kontakt:
- nan wang
- Telefonnummer: +86 029-84777777
- E-Mail: wangnandoc@fmmu.edu.cn
-
-
Shandong
-
Jinan, Shandong, China, 250021
- Shandong Provincial Hospital
-
Kontakt:
- changqing jing
- Telefonnummer: +86 0531-87938911
- E-Mail: jingchangqing@sdfmu.edu.cn
-
Jinan, Shandong, China, 250014
- The First Affiliated Hospital of Shandong First Medical University
-
Kontakt:
- jiankang zhu
- Telefonnummer: +86 0531-89268763
- E-Mail: 249217523@qq.com
-
Qingdao, Shandong, China
- The Affiliated Hospital of Qingdao University
-
Kontakt:
- zhaojian niu
- Telefonnummer: +86 0532-82911847
- E-Mail: niuzhj@hotmail.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Fudan University Shanghai Cancer Center
-
Kontakt:
- Hua Huang, MD, PhD
- Telefonnummer: +86-13816151816
- E-Mail: huahuang@fudan.edu.cn
-
Hauptermittler:
- Hua Huang, MD,PHD
-
Shanghai, Shanghai Municipality, China
- Shanghai General Hospital
-
Kontakt:
- yuan fang
- Telefonnummer: +86 021-63240090
- E-Mail: Fangyuan1231@aliyun.com
-
-
Shanxi
-
Changzhi, Shanxi, China, 046000
- Changzhi People'S Hospital
-
Kontakt:
- liang zong
- Telefonnummer: +86 0355-2024990
- E-Mail: 250537471@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300060
- Tianjin Medical University Cancer Institute&Hospital
-
Kontakt:
- xiangyang yu
- Telefonnummer: +86 022-23109106
- E-Mail: yxynankai@126.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830011
- Affiliated Cancer Hospital of Xinjiang Medical University
-
Kontakt:
- wenbin zhang
- Telefonnummer: +86 0991-7968088
- E-Mail: zwb3216@sina.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
Kontakt:
- panpan yu
- Telefonnummer: +86 0571-88122222
- E-Mail: yupp0571@163.com
-
Hangzhou, Zhejiang, China, 310009
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Kontakt:
- jiaqi chen
- Telefonnummer: +86 0571-87783777
- E-Mail: 2311046@zju.edu.cn
-
Hangzhou, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine
-
Kontakt:
- linghua zhu
- Telefonnummer: +86 0571-86090073
- E-Mail: 3198020@zju.edu.cn
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- Patients voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.
- Age ≥ 18 years and ≤ 70 years.
- Histologically and/or cytologically confirmed gastric cancer.
- No evidence of gastric outlet obstruction or intestinal obstruction.
- No distant metastasis on imaging examination. Initial laparoscopic exploration confirms CY0P1 or CY1P1, without distant organ metastasis, with a recorded peritoneal carcinomatosis index (PCI) ≤ 20, and with either positive or negative ascites. Patients meeting these criteria are eligible for pre-enrollment. Following successful conversion therapy, a second laparoscopic exploration must confirm conversion to CY0P0, with no distant organ metastases and no regional lymph node metastases beyond the second station. Only upon meeting these criteria are patients formally enrolled in the study.
- No prior chemotherapy, targeted therapy, or immunotherapy.
- ECOG performance status score of 0-2.
- Life expectancy ≥ 12 weeks.
- Laboratory requirements: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, platelet count ≥ 75 × 10⁹/L, hemoglobin ≥ 8 g/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 1.5 × ULN. In the presence of liver metastases, AST and ALT ≤ 5 × ULN; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (CCr) ≥ 60 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
Exclusion Criteria:
- Initial laparoscopic exploration reveals P0, or either of the two laparoscopic explorations reveals distant organ metastasis or distant lymph node metastasis.
- Prior anticancer therapy, including chemotherapy, targeted therapy, or immunotherapy.
- Hypertension that cannot be adequately controlled with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).
- Active bleeding or coagulation disorder within 2 months prior to enrollment, bleeding tendency, or ongoing thrombolytic therapy, deemed by the investigator as unsuitable for enrollment.
- Active cardiac disease within 6 months prior to treatment, including myocardial infarction, severe/unstable angina pectoris. Left ventricular ejection fraction (LVEF) < 50% on echocardiography, or poorly controlled arrhythmia.
- Known allergy to immunotherapy agents, chemotherapy agents, or any of their excipients.
- Pregnancy (positive pregnancy test prior to treatment initiation) or breastfeeding.
- Active or uncontrolled severe infection: Severe infection within 4 weeks prior to enrollment (e.g., requiring intravenous antibiotics, antifungals, or antivirals); Known human immunodeficiency virus (HIV) infection; History of clinically significant liver disease, including viral hepatitis. For known hepatitis B virus (HBV) carriers, active HBV infection must be excluded, defined as HBV DNA positive (> 1 × 10⁴ copies/mL or > 2000 IU/mL); Known hepatitis C virus (HCV) infection with positive HCV RNA (> 1 × 10³ copies/mL), or other hepatitis, cirrhosis.
- Urinalysis indicating proteinuria ≥ 2+, with 24-hour urine protein quantification > 1.0 g.
- Any other condition deemed by the investigator as inappropriate for participation in this study.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Surgery Group
|
Patients undergo curative gastrectomy with D2 lymphadenectomy (laparoscopic, robotic, or open) during second-look laparoscopy after successful conversion therapy.
Postoperatively, they receive adjuvant systemic therapy (continuing the preoperative regimen or MDT-modified protocol) for up to 8 cycles total, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.
|
|
Aktiver Komparator: Standard Treatment Group
|
Patients do not undergo surgery.
They continue the original conversion regimen or an MDT-adjusted systemic therapy for a total of 8 cycles, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.
Salvage surgery is permitted if clinically indicated.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Overall Survival (OS)
Zeitfenster: Up to 3 years after randomization
|
Up to 3 years after randomization
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Quality of Life (QoL) assessed by EORTC QLQ-C30 questionnaires
Zeitfenster: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
|
|
Quality of Life (QoL) assessed by EORTC QLQ-STO22 questionnaires
Zeitfenster: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
|
|
Pathological Complete Response (pCR) Rate
Zeitfenster: At the time of radical surgery
|
At the time of radical surgery
|
|
|
R0 Resection Rate
Zeitfenster: At the time of radical surgery
|
At the time of radical surgery
|
|
|
Complication-Free Survival
Zeitfenster: Up to 3 years after randomization
|
Up to 3 years after randomization
|
|
|
Major Complication Rate
Zeitfenster: Within 30 days and 90 days after surgery
|
Within 30 days and 90 days after surgery
|
|
|
Progression-Free Survival (PFS) and Peritoneal PFS
Zeitfenster: Up to 3 years after randomization
|
Up to 3 years after randomization
|
|
|
Time to Peritoneal Re-dissemination
Zeitfenster: Up to 3 years after randomization
|
Up to 3 years after randomization
|
|
|
Length of Hospital Stay
Zeitfenster: Perioperative period
|
Duration of postoperative hospital stay, calculated from the date of surgical intervention to the date of hospital discharge, only applicable to participants receiving surgical treatment.
|
Perioperative period
|
|
Readmission Rate
Zeitfenster: Within 30 days and 90 days post-surgery
|
Within 30 days and 90 days post-surgery
|
|
|
Treatment Interruption Rate
Zeitfenster: Within 1-year after randomization
|
Within 1-year after randomization
|
|
|
Direct Medical Costs / Hospitalization Costs
Zeitfenster: Baseline through study completion, an average of 3-years post-randomization
|
Direct medical costs are defined as all medical expenses directly related to the patient's care, including hospitalization, surgery, medications, laboratory tests, imaging examinations, and management of complications.
Data will be collected continuously throughout the study period (from baseline until death or study completion) and aggregated at the end of the study.
|
Baseline through study completion, an average of 3-years post-randomization
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. Oktober 2026
Primärer Abschluss (Geschätzt)
1. Oktober 2031
Studienabschluss (Geschätzt)
1. Oktober 2031
Studienanmeldedaten
Zuerst eingereicht
23. August 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
26. August 2026
Zuerst gepostet (Tatsächlich)
27. August 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
27. August 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
26. August 2026
Zuletzt verifiziert
1. August 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2606346-6-2608A
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Beschreibung des IPD-Plans
Individual-participant-level raw data will not be shared externally.
Aggregated study results will be published in peer-reviewed journals.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .